The survivability of Parkinson’s disease (PD) in Connecticut reflects a complex interplay of factors including disease progression, healthcare access, patient activity levels, and advances in treatment. Parkinson’s disease is a chronic, progressive neurological disorder that primarily affects movement, and while it is not directly fatal, complications related to the disease can influence mortality.
In Connecticut, Parkinson’s disease mortality has been increasing over recent years. Between 2019 and 2023, the number of deaths attributed to Parkinson’s rose by about 30%, from 362 deaths in 2019 to 471 in 2023. This increase is notable and places Connecticut among the states with a significant surge in Parkinson’s-related deaths. The age-adjusted mortality rate in Connecticut was 9.2 deaths per 100,000 people in 2023, which is higher than it was in 2019 (7.2 per 100,000), indicating a rising trend in mortality despite being mid-ranked nationally. This suggests that while Parkinson’s itself is not immediately fatal, the disease burden and its complications are becoming more prominent in the state’s population[1][3].
Survivability in Parkinson’s disease is influenced by how well symptoms are managed and the overall health and activity level of the patient. Research shows that staying active, especially during hospital stays, significantly improves outcomes for people with Parkinson’s. Patients who maintain frequent mobilization—defined as at least three movements or exercises per day, including walking, standing, or even passive range of motion—have shorter hospital stays and a higher likelihood of returning home rather than to hospice care. Moreover, active patients have a substantially lower risk of death within 30 to 90 days after hospitalization compared to inactive patients. This highlights the critical role of physical activity and rehabilitation in improving survival chances and quality of life for those with Parkinson’s[2].
Treatment advances also contribute to survivability. Deep brain stimulation (DBS), a surgical intervention available to some patients, can reduce symptoms by 50% or more, improving motor function and potentially extending life expectancy by reducing complications related to immobility and falls. Medication regimens tailored to individual symptoms, along with multidisciplinary care involving neurologists, physical therapists, and occupational therapists, are essential components of managing Parkinson’s disease effectively[5].
In Connecticut, community support and awareness efforts also play a role in survivability. Local initiatives, such as fundraising rides and support groups, foster a sense of community and encourage patients to remain engaged and active. These programs not only raise funds for research but also provide emotional and social support, which can positively impact mental health and motivation to adhere to treatment and exercise regimens[4].
The overall survivability of Parkinson’s disease in Connecticut is thus shaped by a combination of rising mortality rates, the benefits of active management, and the availability of advanced treatments and community resources. While the disease remains progressive and incurable, patients who engage in regular physical activity, receive comprehensive care, and benefit from supportive communities tend to have better survival outcomes and quality of life. The increasing mortality rates underscore the need for continued focus on early diagnosis, effective symptom management, and public health strategies to support those living with Parkinson’s in Connecticut.
